A regulatory and compliance roadmap for integrating automated machine learning pipelines into validated pharmaceutical safety organizations.
Health authorities do not permit fully unmonitored AI decision-making in safety reporting: regulatory audits require clear audit trails, validation dossiers, and demonstrable human-in-the-loop oversight under Good Pharmacovigilance Practices (GVP).
AI pharmacovigilance software must be validated according to GAMP 5 Category 4/5 guidelines, establishing IQ/OQ/PQ protocols that prove the machine learning model maintains deterministic precision across version updates.
Safety platforms must account for reporting biases, including the 'Weber effect' (a spike in adverse reporting immediately following new drug launch) and media attention spikes, adjusting statistical baselines accordingly.